Strategic Initiative

Slingshot members are tracking this corporate initiative:

Teva and Checkpoint Therapeutics Announce License Agreement in which Checkpoint will obtain the exclusive worldwide rights to develop and commercialize CEP-8983 and its small molecule prodrug, CEP-9722, an oral poly (ADP-ribose) polymerase

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks



Additional Information

Additional Relevant Details James F. Oliviero, III, President and CEO of Checkpoint Therapeutics stated, “The acquisition of worldwide rights to CEP-9722 immediately transforms Checkpoint Therapeutics into a clinical-stage biopharmaceutical company, expanding our proprietary portfolio with an exciting targeted therapy that, when combined with our immuno-oncology antibodies under development, can potentially create wholly-owned proprietary combinations that leverage the immune system and other complimentary mechanisms with the goal of providing significant benefit to patients. PARP inhibitors have been associated with promising activity across multiple tumor types, including breast, ovarian and prostate cancer.” Mr. Oliviero, continued, “We appreciate Teva’s belief in our organization and our development strategy for this drug candidate in multiple strategic indications.”
Slingshot Insights Explained
Strategic Initiative Date
Announcement Date:
Jan 07, 2016
Projected Implementation:
Q1, 2016
Relevance Tracked Until:
Q4, 2016
Related Projects Image
  • Don’t see a project related to the strategic initiative you care about?

Related Keywords Cep-8983, Cep-9722, Oral Poly Polymerase, Small Molecule Prodrug, Adp-ribose, License Agreement, Exclusive Rights